Drugs News and Research

RSS

New therapeutic vaccines help kick drug habits

A pair of new vaccines designed to combat cocaine and methamphetamine dependencies not only relieve addiction but also minimize withdrawal symptoms, according to study results presented by Baylor College of Medicine (BCM) researchers at the Annual Meeting of the College on Problems of Drug Dependence in Quebec City, Canada.

23 Jun 2007

New drug target for the treatment of Parkinson's disease

Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.

23 Jun 2007

New risk marker for overweight children

A study of 40 overweight children in Edmonton has revealed they all share something in common aside from being heavy: each one of them has high levels of apoB48, a structural protein found in intestinal cholesterol.

23 Jun 2007

New hope for Alzheimer's disease

Scientists have provided new details about how proteins used to destroy bacteria and viruses may help treat Alzheimer?s disease.

23 Jun 2007

Novel method of drug delivery to inhibit the growth of prostate cancer cells

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

23 Jun 2007

Invertebrate immune systems are anything but simple

A hundred years since Russian microbiologist Elie Metschnikow first discovered the invertebrate immune system, scientists are only just beginning to understand its complexity.

23 Jun 2007

Why NSAIDs damage the tissue that lines the gastrointestinal tract

New versions of drugs like buffered aspirin and Vioxx could produce fewer harmful side effects thanks to research being done at Kansas State University's College of Veterinary Medicine.

23 Jun 2007

Inherited genes linked to toxicity of leukemia therapy

St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.

23 Jun 2007

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.

23 Jun 2007

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth.

23 Jun 2007

Novel cellular mechanism that may guide cell movement and possibly cancer cell invasion

Scientists have long thought that microtubules, part of the microscopic scaffolding that the cell uses to move things around in order to hold its shape and divide, originated from a tiny structure near the nucleus, called the centrosome.

23 Jun 2007

Strong work ethic and sense of place delays elderly heart patients from seeking care

A strong work ethic and sense of place appear to influence how elderly rural Albertans with congestive heart failure manage their illness, in that these values may delay them from seeking help at critical times, a University of Alberta study shows.

23 Jun 2007

RNA polymerase points to new targets for drug design

Researchers at UAB (University of Alabama at Birmingham) have new information on the structure of a key enzyme in bacteria that could lead to improved antibiotics and less antibiotic resistance.

23 Jun 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

First genome-scale model of microbe that causes tuberculosis

Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year.

23 Jun 2007

Entecavir can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

23 Jun 2007

Genzyme files for FDA approval of single-treatment Synvisc-One

Genzyme Corp. has announced that it has filed with the U.S. Food and Drug Administration (FDA) for approval of Synvisc-One, the single treatment of Synvisc (hylan G-F 20) that provides up to six months of pain relief from osteoarthritis (OA) of the knee.

23 Jun 2007

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Cross-resistance alarms raised earlier this year by Johns Hopkins researchers about a widely used antiviral therapy for hepatitis B liver infections have prompted swift treatment revisions by the drug's maker and governmental agencies.

23 Jun 2007

Sea-squirt derived drug trabectedin shows promise as cancer treatment

The sea-squirt derived drug trabectedin (ecteinascidinin-743) shows anti-tumour activity in more than half of patients with a specific type of cancer, conclude authors of an article published early Online and in the July edition of The Lancet Oncology.

22 Jun 2007

New trade agreement language to allow developing countries more flexibility in circumventing drug patents, other restrictions

Democratic lawmakers and U.S. trade officials are in the final stages of negotiation over language to be added to international free trade agreements that would allow developing countries more flexibility in circumventing drug patents and other restrictions on pharmaceuticals, sources said recently, CongressDaily reports.

22 Jun 2007